Taxane Anticancer Drugs: Pharmacological Properties and Dosing Strategies

A review paper discusses the pharmacological properties and optimal dosing strategies for major taxane anticancer drugs, including paclitaxel, docetaxel, cabazitaxel, and nab-paclitaxel. The paper, authored by Marsilla Muth from Kantonsspital St. Gallen, provides an overview of metabolism, pharmacokinetics, and the ongoing debate on dosing regimens. It concludes that the value of pharmacological individualization via Therapeutic Drug Monitoring remains largely unexplored for newer taxanes.

Use Cases

• Reviewing pharmacological properties of taxanes based on the overview of metabolism and pharmacokinetics.
• Analyzing debates on optimal dosing regimens based on the discussion of weekly versus 3-weekly schedules.
• Investigating the potential for Therapeutic Drug Monitoring based on the mention of TDM and TCI for taxane personalization.
• Comparing established and newer taxanes based on the description of classical drugs versus cabazitaxel and nab-paclitaxel.

Strengths

• Focuses on four widely used anticancer drugs: paclitaxel, docetaxel, cabazitaxel, and nab-paclitaxel.
• Explicitly discusses multiple aspects of clinical use, including dosing regimens and pharmacological individualization.
• Authored by a researcher affiliated with a hospital (Kantonsspital St. Gallen), suggesting a clinical perspective.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Last update date is unknown; freshness unverified.

Provenance

Source

paperswithcode

Collection Method

Likely contains a literature review and synthesis of existing research.